Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4946236 | 1.00 | POLB (0.57) | POLBHPGDTSHRAMY1AKDM4E | |
| SCHEMBL27984914 | 0.84 | KDM4E (0.55) | POLBHPGDKDM4EL3MBTL1KMT2A | |
| SCHEMBL8731826 | 0.83 | HPGD (0.43) | POLBHPGDTSHRKDM4EL3MBTL1 | |
| SCHEMBL7370491 | 0.83 | HPGD (0.43) | POLBHPGDTSHRKDM4EL3MBTL1 | |
| SCHEMBL27908060 | 0.79 | MAPT (0.44) | POLBHPGDKDM4EL3MBTL1KMT2A | |
| SCHEMBL4697713 | 0.79 | MAPT (0.51) | POLBHPGDKDM4EL3MBTL1KMT2A | |
| SCHEMBL4697709 | 0.79 | MAPT (0.51) | POLBHPGDKDM4EL3MBTL1KMT2A | |
| SCHEMBL914992 | 0.78 | MAPT (0.54) | POLBHPGDKDM4EKMT2AMAPT | |
| SCHEMBL20148160 | 0.78 | KMT2A (0.44) | POLBHPGDTSHRAMY1AKDM4E | |
| SCHEMBL20150808 | 0.78 | KMT2A (0.44) | POLBHPGDTSHRAMY1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1697356-B1 | PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINES AS PDE 2 INHIBITORS | PFIZER PROD INC (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20070135457-A1 | Pyrido[2,3-d]pyrimidine-2,4-diamines as pde2 inhibitors | PFIZER INC. | 2007-06-14 | — | — | US | disclosed |
| EP-1697356-A1 | PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINES AS PDE 2 INHIBITORS | Pfizer Products Incorporated (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005061497-A1 | PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINES AS PDE 2 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135457-A1 | Pyrido[2,3-d]pyrimidine-2,4-diamines as pde2 inhibitors | PDE12, PDE2A, PDE3A | POLB 738/4885HPGD 139/4885TSHR 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.